ClinicalTrials.gg
Not yet recruitingNCT07946705Updated Nov 18, 2026

Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function

An interventional study of Panthea Core and Matched Placebo in Hypertension, sponsored by University of Minnesota. Not yet recruiting at 1 site in United States. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Minnesota · Not applicable, Interventional, and Basic science

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies in Hypertension by University of Minnesota — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · University of Minnesota.

Planned enrollment
10th of 15
60 · median 79
Started
2027
the only one that year
No phase
8 of 23
2 open now
Registered
23rd of 23
by date

Among the 23 studies in Hypertension by University of Minnesota, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2027, is one of 8 with no phase, and was the 23rd registered.

Hypertension

6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 23 studies in Hypertension by University of Minnesota are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.

This study: 45 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hypertension by University of Minnesota, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled pilot study will investigate the effects of an Akkermansia muciniphila-based probiotic supplement, Panthea Core, on autonomic and vascular function in postmenopausal women with hypertension.

Up to 60 participants aged 45 to 65 years will be enrolled to obtain approximately 40 evaluable datasets. Participants will be randomly assigned to receive Panthea Core or a matched placebo capsule daily for 12 weeks.

The study will evaluate safety, tolerability, menopausal symptoms, and changes in autonomic and vascular physiology. The primary mechanistic outcome is muscle sympathetic nerve activity (MSNA), measured using microneurography. Secondary physiological outcomes include heart rate variability, baroreflex sensitivity, endothelial function assessed by flow-mediated dilation, and blood pressure.

Additional assessments will include sleep, menopausal symptoms, mood, cognitive function, circulating metabolic markers, and gut microbiome composition. Participants will complete baseline and post-intervention assessments, with additional safety monitoring throughout supplementation and approximately one month after the intervention.

Read the detailed description

Akkermansia muciniphila is a bacterium normally found in the human gastrointestinal tract that has been associated with metabolic and immune regulation. Previous research suggests that changes in Akkermansia muciniphila abundance may be related to blood pressure regulation, autonomic nervous system function, and vascular health. However, the effects of direct supplementation on human autonomic and endothelial physiology have not been adequately characterized.

This pilot study will evaluate the effects of a 12-week Akkermansia muciniphila-based probiotic supplement, Panthea Core, in postmenopausal women with hypertension. Hypertension is used as a physiological model of autonomic and vascular dysregulation, rather than as a treatment endpoint.

Participants will be randomized to Panthea Core or matched placebo in a double-blind, parallel-group design. The study plans to recruit up to 60 participants to obtain approximately 40 evaluable datasets.

Participants will complete three in-person study visits, including informed consent and two physiological assessment visits. During the baseline and post-intervention assessments, autonomic nervous system activity will be evaluated using microneurography to measure muscle sympathetic nerve activity, electrocardiography to assess heart rate variability, and physiological testing to assess baroreflex sensitivity.

Vascular endothelial function will be assessed using brachial artery flow-mediated dilation. Blood pressure and heart rate will also be measured.

Additional evaluations include laboratory safety measurements, metabolic and hormonal biomarkers, menopausal symptoms, sleep quality, mood, cognition, anthropometric measurements, dietary intake, and stool-based microbiome profiling.

Participants will take their assigned supplement or placebo daily for 12 weeks. Adverse events and gastrointestinal tolerability will be assessed through biweekly questionnaires and participant-initiated reporting. A follow-up contact approximately one month after the final testing visit will assess additional symptoms and adverse events.

The study is intended to generate preliminary mechanistic, safety, and tolerability data to inform the design of subsequent clinical research. As a pilot study, it is not powered to establish definitive treatment efficacy.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Akkermansia muciniphila
  • Panthea Core
  • Probiotics
  • Muscle sympathetic nerve activity
04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female individuals, assigned female sex at birth, aged 45 to 65 years.
  • Clinician-diagnosed hypertension, either controlled or uncontrolled.
  • status, defined as at least 12 months without menstruation or prior surgical removal of the ovaries.
  • Willing and able to provide .

Exclusion criteria

Exclusion Criteria:

  • Nicotine/tobacco, probiotic, or antibiotic use within the previous six months.
  • of 40 kg/m² or greater.
  • Use of hormonal or systemic exogenous hormones.
  • Diagnosis of diabetes.
  • Respiratory disease other than well-controlled asthma.
  • Severe neurological conditions, including traumatic brain injury or stroke.
  • Existing endocrine abnormalities.
  • History of chemotherapy.
  • Surgery within the preceding six months.
  • disorders.
  • History of organ transplantation.
  • Digestive disorders, including active or unstable gastrointestinal disease, major gastrointestinal surgery, or motility disorders.
  • or therapy.
  • Chronic illnesses that preclude participation at the investigator's discretion.
  • Intermittent fasting with unwillingness or inability to complete a four-week before enrollment.
  • Inability to speak, read, or understand English.
  • Inability to provide .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Panthea Core Supplementation

    Participants randomized to this group will receive one daily oral capsule of Panthea Core containing live Akkermansia muciniphila and additional dietary supplement ingredients for 12 weeks. Participants will undergo baseline and post-intervention assessments of autonomic and vascular function, safety, and related physiological outcomes.

    Dietary Supplement: Panthea Core

  • Placebo comparator
    Placebo

    Participants randomized to this group will receive a matched placebo capsule daily for 12 weeks. Participants will undergo the same baseline and post-intervention assessments as those assigned to Panthea Core.

    Dietary Supplement: Matched Placebo

Interventions

  • Dietary supplementPanthea Core

    Panthea Core is an oral probiotic formulation containing live Akkermansia muciniphila (approximately 1 × 10\^8 active fluorescence units), pyridoxal-5'-phosphate (10 mg), spermidine trihydrochloride (1.2 mg), and 3,3'-diindolylmethane (100 mg). Participants will take the formulation once daily for 12 weeks. Study product will be distributed through the Investigational Drug Services Pharmacy.

    Also known as: Akkermansia muciniphila-Based Probiotic, Panthea Core Supplementation

  • Dietary supplementMatched Placebo

    Participants will receive a matched oral placebo capsule administered once daily for 12 weeks. The placebo will be supplied by Panthea Inc. and dispensed through the Investigational Drug Services Pharmacy.

    Also known as: Placebo for Panthea Core, Placebo

06

What researchers measure

Primary outcomes

  1. Change in Muscle Sympathetic Nerve Activity (MSNA)

    Muscle sympathetic nerve activity will be measured using microneurography of the fibular nerve. MSNA burst frequency, expressed as bursts per minute, will be assessed at baseline and after 12 weeks of Panthea Core or placebo supplementation. Changes in MSNA will be compared between treatment groups.

    Time frame: Baseline to 12 weeks

  2. Incidence of Adverse Events

    Adverse events and serious adverse events will be monitored throughout the intervention through biweekly REDCap questionnaires, participant-initiated reports, and post-intervention follow-up. The incidence and nature of adverse events will be summarized by treatment group to evaluate the safety and tolerability of Panthea Core.

    Time frame: From initiation of supplementation through approximately 4 weeks after the 12-week intervention

  3. Change in Comprehensive Metabolic Panel Laboratory Measures

    Safety will be evaluated through changes in comprehensive metabolic panel laboratory measurements, including renal function, liver function, and electrolyte measurements. Laboratory results will be assessed at baseline and after 12 weeks of supplementation and summarized by treatment group.

    Time frame: Baseline and 12 weeks

  4. Supplement Adherence

    Adherence to daily Panthea Core or placebo supplementation will be monitored throughout the intervention using participant-reported information collected through biweekly REDCap questionnaires. Adherence will be summarized descriptively, with a protocol target of at least 80%.

    Time frame: Throughout the 12-week intervention

  5. Study Retention

    Study retention will be assessed as the proportion of enrolled participants who complete the planned intervention and post-intervention assessments. The protocol specifies a retention target of at least 75%.

    Time frame: From enrollment through completion of the 12-week intervention

Secondary outcomes

  1. Change in Flow-Mediated Dilation (FMD)

    Endothelial function will be assessed using brachial artery ultrasound flow-mediated dilation, expressed as percentage change in vessel diameter following temporary forearm occlusion.

    Time frame: Baseline to 12 weeks

  2. Change in Heart Rate Variability (HRV)

    Cardiovagal modulation will be evaluated using time-domain and frequency-domain measures derived from electrocardiogram recordings.

    Time frame: Baseline to 12 weeks

  3. Change in Cardiovagal Baroreflex Sensitivity

    Cardiovagal baroreflex sensitivity will be assessed using changes in ECG R-R intervals relative to changes in systolic blood pressure, expressed in ms/mmHg.

    Time frame: Baseline to 12 weeks

  4. Change in Sympathetic Baroreflex Sensitivity

    Sympathetic baroreflex sensitivity will be evaluated using changes in MSNA relative to diastolic blood pressure, expressed in bursts/100 heartbeats/mmHg as described in the protocol.

    Time frame: Baseline to 12 weeks

  5. Change in Blood Pressure

    Systolic and diastolic blood pressure will be measured at baseline and after the 12-week intervention to assess changes in blood pressure as a physiological parameter.

    Time frame: Baseline to 12 weeks

  6. Change in Menopause-Specific Quality of Life

    Menopausal symptoms and quality of life will be assessed using the Menopause-Specific Quality of Life (MENQOL) questionnaire, including vasomotor, physical, psychosocial, and sexual domains.

    Time frame: Baseline to 12 weeks

  7. Change in Depressive Symptoms (PHQ-9)

    Depressive symptoms will be evaluated using the nine-item Patient Health Questionnaire (PHQ-9).

    Time frame: Baseline to 12 weeks

  8. Change in Insomnia Severity (ISI)

    Insomnia symptoms will be assessed using the seven-item Insomnia Severity Index.

    Time frame: Baseline to 12 weeks

  9. Change in Subjective Sleep Quality (PSQI)

    (PSQI) Subjective sleep quality and disturbances will be assessed using the Pittsburgh Sleep Quality Index.

    Time frame: Baseline to 12 weeks

  10. Change in Objective Sleep Parameters

    Sleep will be measured using WatchPAT ONE-M monitoring before baseline and post-intervention physiological testing.

    Time frame: Baseline to 12 weeks

  11. Change in Cognitive Function (MoCA)

    Cognitive function will be evaluated using Montreal Cognitive Assessment scores before and after supplementation.

    Time frame: Baseline to 12 weeks

  12. Change in Gut Microbiome Composition

    Fecal microbiome sequencing will be used to evaluate changes in microbial composition and the abundance of Akkermansia muciniphila after supplementation.

    Time frame: Baseline to 12 weeks

07

Study locations

1 site
  • University of Minnesota - Children's Rehabilitation Center
    Minneapolis, Minnesota 55455, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Jan 2030, 35 months later.

Of 1,406 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 35 months is above that.

Counting every sponsor, half of 1,501 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Jan 31, 2030
CompletionEst.
Jan 31, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946705
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Jan 31, 2030 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Manda Keller-Ross
Contact
kell0529@umn.edu
612-625-3175
Emma Lee
Contact
leex4357@umn.edu
612-301-8617
Manda Keller-Ross
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion